NeuroVive Pharmaceutical AB EBITDA margin
Was ist das EBITDA margin von NeuroVive Pharmaceutical AB?
EBITDA margin von NeuroVive Pharmaceutical AB ist -79,544.30%
Was ist die Definition von EBITDA margin?
EBITDA margin is a profitability ratio that measures how much EBITDA the company generates as a percentage of revenue.
ttm (trailing twelve months)
EBITDA margin measures how much of EBITDA is generated as a percentage of sales. It measures the company’s operating profit as a percentage of its revenue and is calculated as EBITDA (earnings before interest, taxes, depreciation, and amortization) divided by total revenue.
EBITDA margin also helps with judging the effectiveness of cost-cutting processes at the company. The higher the company’s EBITDA margin, the lower operating expenses are in respect to revenue. As a result, a higher EBITDA margin is considered more favorable. Smaller companies can have higher EBITDA margins since they are able to operate more efficiently and maximize their profitability.
EBITDA excludes interest on debt, taxes, and capital expenditures, the margin does not provide a perfectly clear estimate of the business’s cash flow generation. Furthermore, EBITDA margin is not recognized as a GAAP (generally accepted accounting principles) metric.
EBITDA margin von Unternehmen in Health Care Sektor auf OTC im Vergleich zu NeuroVive Pharmaceutical AB
Was macht NeuroVive Pharmaceutical AB?
Abliva AB (publ), a pharmaceutical company, engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in Phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.
Unternehmen mit ebitda margin ähnlich NeuroVive Pharmaceutical AB
- Eagle Mountain Mining hat EBITDA margin von -80,928.28%
- RosCan Gold hat EBITDA margin von -80,206.96%
- Cannonau hat EBITDA margin von -80,183.27%
- Revolution Medicines Inc hat EBITDA margin von -80,180.19%
- NeuroVive Pharmaceutical AB hat EBITDA margin von -79,734.59%
- Carbios SA hat EBITDA margin von -79,708.33%
- NeuroVive Pharmaceutical AB hat EBITDA margin von -79,544.30%
- CropLogic hat EBITDA margin von -79,147.31%
- Seneca Biopharma Inc hat EBITDA margin von -78,278.65%
- Karuna Therapeutics Inc hat EBITDA margin von -75,393.88%
- Accelerate Resources hat EBITDA margin von -75,249.13%
- Pacific American hat EBITDA margin von -72,236.00%
- Mako Gold hat EBITDA margin von -72,194.15%